A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailprint

June 17, 2008

Experimental HIV Drug Hits Snag

Development of Koronis Pharmaceuticals’ KP-1461, an experimental antiretroviral (ARV), has been suspended after an analysis of existing data failed to show anti-HIV activity, according to a report by Project Inform. These results came as a surprise to Koronis and stand in contrast to the drug’s earlier lab studies that showed promise.

Though KP-1461 is technically a nucleoside reverse transcriptase inhibitor (NRTI), its mechanism of action is quite different from other drugs in this class of ARVs. Whereas current NRTIs are incorporated into developing DNA to stop the chains of genetic material from becoming fully formed and infectious, the integration of KP-1461 into developing chains of viral DNA causes the virus to produce defective, harmless versions of itself.

The U.S. Food and Drug Administration (FDA) had asked Koronis to do some additional lab studies to determine if HIV becomes resistant to KP-1461. During these lab studies, Koronis found that the drug had no measurable effect on HIV, a stark contrast to earlier studies that supported the drug’s clinical development. With the new results in hand, Koronis then analyzed blood samples from people enrolled in its ongoing clinical trial and, to their surprise, again found no anti-HIV activity.

Stephen Becker, MD, the lead investigator for Koronis, told Project Inform that the company is, “committed to understanding these discordant results and will attempt to validate the original 2002 research,” on KP-1461. Becker estimated that it will take at least two months to fully investigate this setback, and determine what comes next.

Search: Koronis, KP-1461, Stephen Becker, NTRI


Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 6 (of 6 total)    

Lynette, Johannesburg, 2008-07-05 15:08:48
On behalf of LYNETTE I'm 43yrs,female South African with HIV 5yrs now. CD count at 0 sometimes. Family revives me with CELLFOOD OLIVE LEAVE TINCTURE & MANGOSTEEN but can hardly afford it - I don't work, have a huge liver and a disfigured body and face from constant puss pimples. Please Help I need to sign on for Trial RALTEGRAVIR/ISENTRESS-do I qualify as a candidate or where can I sign on please? I made it this far and I have so much to live for please help........God bless Lynette

Jessica, , 2008-06-26 02:00:28
Someone suspect that Koronis presented false result to FDA (serial passagges to extinguish the virus ). If this is confirmed it will be not possible to trust anymore to FDA. I remember what said Stephen Becker. Several series of in vitro experiments were done in cell cultures, using a very nasty strain of IV ( not HIV ? )After an average 15 serial passages, that virus was irreversibly extinguished -- repeatedly. Repeated, published experiments have demonstrated that you can collapse the hiv

paul, , 2008-06-20 06:09:17
I just got a confidential report from MIT in Boston. In few words The scientitist that were more involved -MIT- when the drug was invented, the chemistry phase, confirm that the kp-1212-1461,the 5-substituted cytosine, does extinguish HIV. They are very happy that the company is pushing ahead and they are pleased with the excellent safety profile for KP-1461 and clinical results that show only occasional mild to moderate drug-related adverse.

paul, , 2008-06-19 05:44:30
They asked the people, in a very bad condition, to stop 16 weeks the haart for which reason? to be enrolled in a trial to test a drug that is like water? IF yes .. it is crime. I think there is something really strange in all this "stuff". I m looking forward for more deeply details from Koronispharma.

paul, , 2008-06-18 10:19:41
There has to be a twist. It is not possible that FDA permit a clinical trial phase 2 for a hiv drug that is simple water. It is not possible at all.....FDA must have required all the possible datas before giving green light to Koronis for humans trial..There has to be a twist. What about the pacific ventures funds? Big job for the lawyer on the horizon ?

johnny1, , 2008-06-18 02:33:38
In the projectinform report is written that few people experienced significant reductions in their HIV levels. Few people is completely different than no people. It means that kp-1461 in some(few people ) can really controll the hiv replication. The mechanism's theory is valid, it is a matter of finding the correct chemical structure to be inserted into the virus' life cycle.

comments 1 - 6 (of 6 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    CuteBoyinQns
    Jackson Heights
    New York


    Hillcrester
    Ramona
    California


    vinamarino94
    new york city
    New York


    ZealousBrother
    Baltimore
    Maryland
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.